**Retrospective case series of Acthar treatment for proteinuria in 44 patients with various etiologies of nephrotic syndrome**

Largest-to-date Acthar clinical experience in a majority of patients who received previous therapies

**Acthar Gel in the Treatment of Nephrotic Syndrome: a Multicenter Retrospective Case Series**


This retrospective case series is the largest-to-date clinical experience with Acthar, an FDA-approved naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides, for the reduction of proteinuria associated with various etiologies of nephrotic syndrome.

Presentation of study design, baseline characteristics, efficacy, and safety findings within this summary are based on content from Madan et al, 2016, where proteinuria reduction was evaluated as a treatment outcome. Impact on renal function as part of the outcome definition was not reported for the entire population.

A post hoc analysis was then conducted by Mallinckrodt that assessed treatment response to Acthar based on a compound primary outcome measure that included both reduction in proteinuria and stable or improved renal function (creatinine ≤125% of baseline or eGFR ≥75% of baseline). This compound outcome measure aligns with the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines recommendations for assessing treatment response to nephrotic syndrome therapy.

The original research was performed under a grant from Mallinckrodt. The post hoc analysis, using the compound outcome measure for response, was reviewed and approved by the primary and senior authors of the original paper. All data needed to perform the analysis were presented in the original paper.

**Indication**

Acthar® Gel (repository corticotropin injection) is indicated to induce a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.

**SELECT IMPORTANT SAFETY INFORMATION**

**Contraindications**

- Acthar should never be administered intravenously
- Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
- Acthar is contraindicated where congenital infections are suspected in infants
- Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

Please see additional Important Safety Information throughout and on page 7. Please see the accompanying full Prescribing Information.
Retrospective case series of Acthar gel treatment for proteinuria in 44 patients with various etiologies of nephrotic syndrome

Overview

A multicenter retrospective review of 44 patients with various nephrotic syndrome (NS) etiologies examined the efficacy and safety of Acthar for the reduction of proteinuria. The majority (30/44) had received ≥1 previous cytotoxic or immunosuppressive therapy. The remaining 14 patients were treatment naïve.

Patients ≥18 years diagnosed with NS received Acthar treatment for ≥6 months and had an assessment of either 24-hour proteinuria level (mg/d) or UPCR (g/g converted to mg/d) prior to and following 6 months of Acthar therapy. Patients did not have to meet a prespecified level of proteinuria at baseline to be included in the study.

Cases included 44 patients across the following NS etiologies:

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal Segmental Glomerulosclerosis (FSGS)</td>
<td>15</td>
</tr>
<tr>
<td>Idiopathic Membranous Nephropathy (iMN)</td>
<td>11</td>
</tr>
<tr>
<td>IgA Nephropathy (IgAN)</td>
<td>5</td>
</tr>
<tr>
<td>Systemic Lupus Erythematosus Class V Membranous Lupus Nephritis (MLN)</td>
<td>2</td>
</tr>
<tr>
<td>Minimal Change Disease (MCD)</td>
<td>2</td>
</tr>
<tr>
<td>Membranoproliferative Glomerulonephritis (MPGN)</td>
<td>1</td>
</tr>
<tr>
<td>Fibrillary Glomerulonephritis (FGN)</td>
<td>1</td>
</tr>
<tr>
<td>Unbiopsied NS (UNS)</td>
<td>3</td>
</tr>
<tr>
<td>Diabetic Nephropathy* (DN)</td>
<td>4</td>
</tr>
</tbody>
</table>

*Individual results of the 4 patients with DN are not included in this presentation. Acthar is not indicated to reduce proteinuria associated with DN.

Acthar® Gel (repository corticotropin injection) is indicated to induce a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

- Acthar should never be administered intravenously
- Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
- Acthar is contraindicated where congenital infections are suspected in infants
- Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

Please see additional Important Safety Information throughout and on page 7. Please see the accompanying full Prescribing Information.

Acthar® Gel (repository corticotropin injection) 80 IU/mL

You may find more information about this study at BMC Nephrology or at PubMed.gov.

Design

Week 0 Week 2 4 80 IU ACTHAR SC BIW

n=15 FSGS

n=11 iMN*

n=5 IgAN

n=2 MLN

n=3 MCD

n=1 MPGN

n=1 FGN

n=3 Unbiopsied NS

n=4 DN

n=44

*One patient with iMN was treated with Acthar 40 IU.

†Patients were prescribed Acthar for a minimum of 24 weeks; actual treatment durations varied.

Acthar dosing regimen and concomitant medications, including angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, and immunosuppressive and cytotoxic drugs, were documented.

Dosing of Acthar (as stated in Prescribing Information): Dosage and frequency of Acthar should be individualized according to the medical condition, severity of the disease, and initial response of the patient.

- The usual dose of Acthar is 40 to 80 units given intramuscularly or subcutaneously every 24 to 72 hours

Outcome Measures

Outcome measures evaluated in the case series included:

- Responses that were defined as:
  - Complete Remission (CR): stable or improved renal function (serum creatinine that did not worsen >25% from baseline) and final proteinuria <500 mg/d
  - Partial Remission (PR): stable or improved renal function (serum creatinine that did not worsen >25% from baseline) with ≥50% reduction in proteinuria from baseline and final proteinuria 500–3500 mg/d
  - Clinical Response (CR): ≥30% reduction in proteinuria from baseline that did not meet CR or PR criteria
  - No Response (NR): patients showing no response failed to meet remission or CR criteria
- Frequency of adverse events and early discontinuation due to adverse events

Additional laboratory measures included change in serum creatinine, albumin, and total cholesterol if data were available.

Links to: https://www.ncbi.nlm.nih.gov/pubmed

Links to: https://bmcnephrol.biomedcentral.com/
SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- The adverse effects of Acthar are related primarily to its steroidogenic effects.
- Acthar may increase susceptibility to new infection or reactivation of latent infections.
- Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment.

Please see additional Important Safety Information throughout and on page 7. Please see the accompanying full Prescribing Information.

Patient Baseline Characteristics

Among the 44 patients, the majority (30/44; 68.2%) had received ≥1 prior immunosuppressive or cytotoxic therapy and 20 of 44 (45.5%) had received ≥2 prior immunosuppressive and/or cytotoxic treatments.

### Patient Baseline Characteristics

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Previously Used IST or CT (n/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSGS</td>
<td>12/15</td>
</tr>
<tr>
<td>IMN</td>
<td>10/11</td>
</tr>
<tr>
<td>IgAN</td>
<td>1/5</td>
</tr>
<tr>
<td>MLN</td>
<td>2/2</td>
</tr>
<tr>
<td>MCD</td>
<td>2/2</td>
</tr>
<tr>
<td>MPGN</td>
<td>0/1</td>
</tr>
<tr>
<td>FGN</td>
<td>1/1</td>
</tr>
<tr>
<td>Unbiopsied NS</td>
<td>2/5</td>
</tr>
<tr>
<td>DN</td>
<td>0/4</td>
</tr>
</tbody>
</table>

68.2% of patients (n=30/44) were previously treated with ≥1 of the following:

- steroids
- mycophenolate mofetil
- cyclosporine
- cyclophosphamide
- tacrolimus
- azathioprine
- methotrexate
- chlorambucil
- rituximab

31.8% of patients (n=14/44) received no previous IST/CT

### Patient Baseline Characteristics (continued)

Characteristics of patients by NS etiology group are presented below. Over half of patients (26/44; 59.1%) showed impaired renal function prior to Acthar treatment.

<table>
<thead>
<tr>
<th>Etiology</th>
<th>(n)</th>
<th>Age±SD (years)</th>
<th>Serum Albumin* (g/dL)</th>
<th>Serum Creatinine* (mg/dL)</th>
<th>Proteinuria* (mg/d)</th>
<th>Median Proteinuria* (mg/d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSGS</td>
<td>15</td>
<td>53.3±12.9</td>
<td>1.7–3.9</td>
<td>0.9–4.8</td>
<td>2500–9306</td>
<td>5000</td>
</tr>
<tr>
<td>IMN</td>
<td>11</td>
<td>53.6±18.9</td>
<td>1.4–3.9</td>
<td>0.9–3.3</td>
<td>1930–15,400</td>
<td>5210</td>
</tr>
<tr>
<td>IgAN</td>
<td>5</td>
<td>35.0±18.4</td>
<td>3.0–4.0</td>
<td>1.0–2.8</td>
<td>2230–10,000</td>
<td>2674</td>
</tr>
<tr>
<td>MLN</td>
<td>2</td>
<td>37.5±14.9</td>
<td>1.7–1.8</td>
<td>1.0</td>
<td>8000–19,890</td>
<td>13,945</td>
</tr>
<tr>
<td>MCD</td>
<td>2</td>
<td>33.5±13.4</td>
<td>2.1–3.7</td>
<td>0.9–1.0</td>
<td>2000–15,000</td>
<td>8500</td>
</tr>
<tr>
<td>MPGN</td>
<td>1</td>
<td>22.0</td>
<td>1.5</td>
<td>0.7</td>
<td>10,000</td>
<td>10,000</td>
</tr>
<tr>
<td>FGN</td>
<td>1</td>
<td>63.0</td>
<td>1.4</td>
<td>5.6</td>
<td>13,000</td>
<td>13,000</td>
</tr>
<tr>
<td>Unbiopsied NS</td>
<td>3</td>
<td>55.7±6.1</td>
<td>3.1–3.5</td>
<td>1.3–1.7</td>
<td>3000–5500</td>
<td>4500</td>
</tr>
<tr>
<td>DN</td>
<td>4</td>
<td>54.0±19.9</td>
<td>2.0–3.4</td>
<td>1.9–4.8</td>
<td>11,000–25,000</td>
<td>15,785</td>
</tr>
</tbody>
</table>

*Values based on patients for whom data were available.
†Median proteinuria adapted from reported proteinuria values given for each patient.

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions (cont.)

- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium, and potassium levels may need to be monitored.
- Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy.
- Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding.

Please see additional Important Safety Information throughout and on page 7. Please see the accompanying full Prescribing Information.

There was significant proteinuria reduction from baseline to post-Acthar treatment for patients with pre- and post-Acthar proteinuria values (n=40; mean reduction 3964.8±4068.1 mg/d, P=0.0001).<sup>1</sup>

Of the 44 patients, 4 patients did not have follow-up proteinuria values.<sup>1</sup>

Response rates from the 37 of 44 patients who completed Acthar treatment

- **56.8%** of patients (21/37) achieved Complete Remission
- **45.9%** of patients (17/37) achieved Partial Remission
- **24.3%** (9/37) achieved Clinical Response

Post hoc analysis outcome: reduction in proteinuria and stable or improved renal function<sup>2</sup>

- **51.4%** of patients (19/37) achieved Complete Remission
- **40.5%** (15/37) achieved Partial Remission
- **18.9%** (7/37) achieved Clinical Response

Study Limitations

Results are based on a retrospective case series of 44 patients and may not be fully representative of outcomes in the overall patient population. Most patients were on multiple therapies. The clinical outcomes may not be solely attributable to Acthar. Of the 44 patients, 37 completed treatment and 7 terminated early.<sup>1,2</sup>

Outcome Measures

- **Complete Remission** of stable or improved renal function (serum creatinine that did not worsen >25% from baseline) and final proteinuria <500 mg/d.
- **Partial Remission** of stable or improved renal function (serum creatinine that did not worsen >25% from baseline) with ≥30% reduction in proteinuria from baseline that did not meet complete or partial remission criteria.

- **Clinical Response** of patients (≥30% reduction in proteinuria from baseline that did not meet complete or partial remission criteria. No Response=patients showing no response failed to meet remission or clinical response criteria).

†Treatment outcome definitions from Madan et al, 2016 publication<sup>1</sup>

‡Treatment outcome definitions from the post hoc analysis 2

- Complete Remission=stable or improved renal function (serum creatinine that did not worsen >25% from baseline and final proteinuria 500–3500 mg/d).
- Partial Remission=stable or improved renal function (serum creatinine that did not worsen >25% from baseline) with ≥30% reduction in proteinuria from baseline and final proteinuria ≥500–1000 mg/d.
- Clinical Response=≥30% reduction in proteinuria from baseline that did not meet complete or partial remission criteria. No Response=patients showing no response failed to meet remission or clinical response criteria.

Includes patient who terminated early but had post-Acthar proteinuria assessment.

Includes patients who terminated early and did not have post-Acthar proteinuria assessment.

Adapted from Madan et al, 2016. Figure reports results for all patients (n=40). Results from 4 patients with DN are not included. Acthar is not indicated to reduce proteinuria associated with DN. Other includes 1 patient with MPGN, 1 patient with FGN, and 3 patients with unbiopsied NS.

Adapted from Madan et al, 2016. Figure reports results for all patients (n=40). Results from 4 patients with DN are not included. Acthar is not indicated to reduce proteinuria associated with DN. Other includes 1 patient with MPGN, 1 patient with FGN, and 3 patients with unbiopsied NS.

Efficacy

Please see the accompanying full Prescribing Information.
Changes in proteinuria levels from baseline across multiple etiologies of NS*1

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Proteinuria Pre-Acthar</th>
<th>Proteinuria Post-Acthar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unbiopsied NS</td>
<td>12,000</td>
<td>5,100</td>
</tr>
<tr>
<td>MPGN</td>
<td>14,000</td>
<td>6,900</td>
</tr>
<tr>
<td>MCD</td>
<td>18,000</td>
<td>7,800</td>
</tr>
<tr>
<td>MLN</td>
<td>14,000</td>
<td>6,900</td>
</tr>
<tr>
<td>IgAN†</td>
<td>18,000</td>
<td>7,800</td>
</tr>
<tr>
<td>iMN</td>
<td>18,000</td>
<td>7,800</td>
</tr>
<tr>
<td>FSGS†</td>
<td>18,000</td>
<td>7,800</td>
</tr>
<tr>
<td>FGN</td>
<td>18,000</td>
<td>7,800</td>
</tr>
</tbody>
</table>

Adapted from Madan et al, 2016.

Figure includes all patients with post-Acthar proteinuria values, with the exception of 4 patients with DN (n=36).

†Includes a patient who terminated early but had post-Acthar proteinuria assessment.

Study Limitations1,2

Results are based on a retrospective case series of 44 patients and may not be fully representative of outcomes in the overall patient population. While this review includes a diverse set of NS etiologies, a significant limitation is small patient numbers in several of the etiology subgroups and a retrospective design without a control group. Because initiation of treatment was based on the judgment of the treating clinician, excluding the IgAN group, 8 patients began treatment at a non-nephrotic proteinuria level <3500 mg/d. Most patients were on multiple therapies. The clinical outcomes may not be solely attributable to Acthar. Longer treatment duration and follow-up may be needed for meaningful treatment responses. The relapse rate following successful treatment with Acthar is not yet known.

Safety Findings1

Adverse events during Acthar treatment were reported by 30% (13/44) of patients, and 16% (7/44) had early termination due to treatment-related adverse events. These results are summarized below.

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Number of Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight gain</td>
<td>7</td>
</tr>
<tr>
<td>Hypertension</td>
<td>4</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>4</td>
</tr>
<tr>
<td>Increased swelling</td>
<td>1</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>1</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>1</td>
</tr>
<tr>
<td>Seizures</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reason for Early Termination</th>
<th>Number of Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight gain</td>
<td>2</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1</td>
</tr>
<tr>
<td>Edema</td>
<td>1</td>
</tr>
<tr>
<td>Seizures</td>
<td>1</td>
</tr>
<tr>
<td>Patient decision</td>
<td>1</td>
</tr>
<tr>
<td>Reason not given</td>
<td>1</td>
</tr>
</tbody>
</table>

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions (cont.)

- Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions.
- Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
- There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
- Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients

Please see additional Important Safety Information throughout and on page 7.
Please see the accompanying full Prescribing Information.
Individual FSGS Patient Results

60% (9/15) of patients with FSGS achieved Partial Remission based on proteinuria reduction

47% (7/15) of patients with FSGS achieved Partial Remission based on proteinuria reduction and stable or improved renal function

Patient demonstrated Partial Remission before terminating treatment early.

Complete Remission, partial remission, and clinical response included both proteinuria reduction, as defined by Madan et al, and stable or improved renal function (serum creatinine that did not worsen >25% from baseline) with ≥50% reduction in proteinuria from baseline and final proteinuria 500–3500 mg/d.

Clinical Response=30% reduction in proteinuria from baseline that did not meet complete or partial remission criteria.

No Response=patients showing no response failed to meet remission or clinical response criteria.

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions (cont.)

• Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy.

• Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Please see additional Important Safety Information throughout and on page 7. Please see the accompanying full Prescribing Information.

Individual iMN Patient Results

55% (6/11) of patients with iMN achieved Complete or Partial Remission based on proteinuria reduction

55% (6/11) of patients with iMN achieved Complete or Partial Remission based on proteinuria reduction and stable or improved renal function

Acthar is indicated to reduce proteinuria of nephrotic syndrome. The impact of Acthar on other relevant lab values has not been more formally assessed and is included here for clinical context only.

Results are based on a retrospective case series of 44 patients and may not be fully representative of outcomes in the overall patient population. Most patients were on multiple therapies. The clinical outcomes may not be solely attributable to Acthar.

Please see the accompanying full Prescribing Information.
‡Patient demonstrated Partial Remission before terminating treatment early.

be solely attributable to Acthar.1,2

not be fully representative of outcomes in the overall patient population.

Acthar is indicated to reduce proteinuria of nephrotic syndrome. The impact

* Complete Remission=stable or improved renal function (serum creatinine that did not worsen >25% from baseline) and final proteinuria <500 mg/d. Partial Remission=stable or

≥30% reduction in proteinuria from baseline that did not meet complete or partial remission criteria. No Response=patients showing no response failed to

≥improved renal function (serum creatinine that did not worsen >25% from baseline).2

Serum Albumin

(Initial Final Initial Final Initial Final
Serum Creatinine

(Mg/dL) (Mg/dL)

Initial Final

Initial Final

Initial Final

Proteinura

Change (%) Proteinuria-Based Response* Proteinuria and Renal Function-Based Response**

4 IgAN 3.0 4.0 1.0 1.0 10,000 800 –92.0

5 IgAN NA 4.2 1.3 1.3 2230 815 –65.5

2 IgAN 3.9 NA 1.4 1.5 2674 1700 –36.4

3 IgAN 4.0 3.6 1.3 1.3 2439 2360 –3.2

1 IgAN 3.9 NA 2.8 2.8 4000 NA NA

2 MLN 1.7 2.4 1.0 1.1 19,890 2454 –87.7

1 MLN 1.8 3.3 1.0 0.8 8000 1089 –86.4

2 MCD 2.1 2.3 1.0 0.7 15,000 89 –99.4

1 MCD 3.7 4.7 0.9 1.2 2000 241 –88.0

-- FGN 1.4 3.4 5.6 9.0 13,000 10,000 –23.1

-- MPGN 1.5 3.3 0.7 0.8 10,000 2141 –78.6

2 UNS 3.5 4.0 1.7 1.9 4500 2000 –55.6

1 UNS 3.5 4.6 1.6 2.2 3000 1600 –46.7

3 UNS 3.1 3.3 1.3 1.3 5500 NA NA

Complete Remission

Partial Remission

Clinical Response

No Response

Early Termination

Other adverse events reported are included in the accompanying full Prescribing Information.

Please see the accompanying full Prescribing Information.


Individual Patient Results for IgAN and Other Etiologies1

IgAN

IgAN

MCD

MLN

FGN

MPGN

Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2020 Mallinckrodt. US-2000587 04/20

Warnings and Precautions

The adverse effects of Acthar are related primarily to its steroidogenic effects

Acthar may increase susceptibility to new infection or reactivation of latent infections

Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment

Cushing’s syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms

Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium, and potassium levels may need to be monitored

Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy

Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding

Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated

Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myocardia gravis

Prolonged use of Acthar may produce cataracts, glaucoma, and secondary ocular infections. Monitor for signs and symptoms

Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity

There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver

Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients

Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy

Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Adverse Reactions

Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose
tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite, and weight gain

Specific adverse reactions reported in its clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some patients progress to other forms of seizures and I5 sometimes mask other seizures, which become visible once the clinical spasms from IS resolve

Important Safety Information

Contraindications

Acthar should never be administered intravenously

Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar

Acthar is contraindicated where congenital infections are suspected in infants

Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adenocortical hyperfunction, or sensitivity to proteins of porcine origin

Importantly, safety information relating to allergic reactions is reported in the Summary of Product Characteristics:

Warnings and Precautions in the course of therapy. If a patient shows prolongation of the recovery period, the dose should be reduced; if the clinical picture does not improve, or deteriorates, the use of Acthar should be discontinued. The use of other corticosteroids should be considered.

Acthar is indicated to reduce proteinuria of nephrotic syndrome. The impact of Acthar on other relevant lab values has not been more formally assessed and is included here for clinical context only.

Results are based on a retrospective case series of 44 patients and may not be fully representative of outcomes in the overall patient population.

Most patients were on multiple therapies. The clinical outcomes may not be solely attributable to Acthar.1,2


Contraindications

Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adenocortical hyperfunction, or sensitivity to proteins of porcine origin

Acthar should never be administered intravenously

Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar

Acthar is contraindicated where congenital infections are suspected in infants

Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adenocortical hyperfunction, or sensitivity to proteins of porcine origin

Warnings and Precautions

The adverse effects of Acthar are related primarily to its steroidogenic effects

Acthar may increase susceptibility to new infection or reactivation of latent infections

Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment

Cushing’s syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms

Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium, and potassium levels may need to be monitored

Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy

Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding

Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated

Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myocardia gravis

Prolonged use of Acthar may produce cataracts, glaucoma, and secondary ocular infections. Monitor for signs and symptoms

Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity

There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver

Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients

Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy

Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Adverse Reactions

Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose
tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite, and weight gain

Specific adverse reactions reported in its clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some patients progress to other forms of seizures and I5 sometimes mask other seizures, which become visible once the clinical spasms from IS resolve

Other adverse events reported are included in the accompanying full Prescribing Information.

Please see the accompanying full Prescribing Information.
WARNINGS AND PRECAUTIONS

• Treatment of conditions listed within the INDICATIONS AND USAGE section is contraindicated when they are accompanied by primary adrenocortical insufficiency or pituitary-axis suppression after stopping treatment. (5.2)

• Gastrointestinal Perforation and Bleeding: There is a risk for gastric ulcers and bleeding. It may be necessary to taper the dose. (2.3)

• Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses. (5.4)

• Vaccination: Do not administer live or live attenuated vaccines to patients on immunosuppressive doses. (5.4)

• Masking of Symptoms of Other Underlying Disease/Disorders. Monitor patients for signs of other underlying disease/disorders that may be masked. (5.5)

• Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses. (5.4)

• Vaccination: Do not administer live or live attenuated vaccines to patients on immunosuppressive doses. (5.4)

• Masking of Symptoms of Other Underlying Disease/Disorders. Monitor patients for signs of other underlying disease/disorders that may be masked. (5.5)

• Gastrointestinal Perforation and Bleeding: There is a risk for gastric ulcers and bleeding. There is an increased risk of perforation in patients with certain GI disorders. Signs and symptoms may be masked. Monitor for signs of perforation and bleeding. (5.6)

• Behavioral and Mood Disturbances. May include euphoria, insomnia, mood swings, personality changes, severe depression and psychosis. Existing conditions may be aggravated. (5.7)

• Comorbid Diseases: Symptoms of diabetes and myasthenia gravis may be worsened with treatment. (5.8)

• Ophthalmic Effects: Monitor for cataracts, infections and glaucoma. (5.9)

• Immune Response Potential: Neutralizing antibodies with chronic administration may lead to a loss of endogenous ACTH activity. (5.10)

• Use in Patients with Hypothyroidism or Liver Cirrhosis: May result in an enhanced effect. (5.11)

• Negative Effects on Growth and Physical Development: Monitor pediatric patients on long term therapy. (5.12)

• Decrease in Bone Density: Monitor for osteoporosis in patients on long term therapy. (5.13)

• Use in Pregnancy: Embryocidal effect. Apprise women of potential harm to the fetus. (5.14)

• Common adverse reactions for Acthar Gel are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain. (6)

ADVERSE REACTIONS

Common adverse reactions for Acthar Gel are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain. (6)

• Use in Pregnancy: Embryocidal effect. Apprise women of potential harm to the fetus. (8.1)

• Pediatric Use: Prolonged use of Acthar Gel in children may inhibit skeletal growth. If use is necessary, it should be given intermittently with careful observation. (5.12 and 8.4)

See 17 for Patient Counseling Information and FDA-approved Medication Guide

FULL PRESCRIBING INFORMATION: CONTENTS*

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Infantile spasms

1.2 Multiple Sclerosis

1.3 Rheumatic Disorders

1.4 Collagen Diseases

1.5 Dermatologic Diseases

1.6 Allergic States

1.7 Ophthalmic Diseases

1.8 Respiratory Diseases

1.9 Edematous State

2 DOSAGE AND ADMINISTRATION

2.1 Specific Recommended Dosage Regimen for Infantile Spasms in Infants and Children Under 2 Years of Age

2.2 Recommended Dosage Regimen for the Treatment of Acute Exacerbations in Adults with Multiple Sclerosis

2.3 Recommended Dosage Regimen for Other Indications for Adults and Children Over 2 Years of Age

2.4 Preparation

3 DOSAGE FORMS AND STRENGTHS

5 WARNINGS AND PRECAUTIONS

5.1 Infections

5.2 Cushing’s Syndrome and Adrenal Insufficiency Upon Withdrawal

5.3 Elevated Blood Pressure, Salt and Water Retention and Hypokalemia

5.4 Vaccination

5.5 Masking of Symptoms of Other Diseases

5.6 Gastrointestinal Perforation and Bleeding

5.7 Behavioral and Mood Disturbances

5.8 Comorbid Diseases

5.9 Ophthalmic Effects

5.10 Immune Response Potential

5.11 Use in Patients with Hypothyroidism or Liver Cirrhosis

5.12 Negative Effects on Growth and Physical Development

5.13 Decrease in Bone Density

5.14 Use in Pregnancy

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

6.1.1 Adverse Reactions in Infants and Children Under 2 Years of Age

6.2 Postmarketing Experience

6.2.1 Allergic Reactions

6.2.2 Cardiovascular

6.2.3 Dermatologic

6.2.4 Endocrine

6.2.5 Gastrointestinal

6.2.6 General Disorders and Administration Site Conditions

6.2.7 Metabolic

6.2.8 Musculoskeletal

6.2.9 Neurological

6.3 Possible Additional Steroidogenic Effects

6.3.1 Dermatologic

6.3.2 Endocrine

6.3.3 Metabolic

6.3.4 Musculoskeletal

6.3.5 Neurological

6.3.6 Ophthalmic

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

10 OVERDOSE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED / STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed

Revised: 3/2019
Acthar Gel (repository corticotropin injection) is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age.

Multiple Sclerosis
Acthar Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that reflects the ultimate outcome or natural history of the disease.

Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis.

Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis).

Dermatologic Diseases
Severe erythema multiforme, Stevens-Johnson syndrome.

Allergic States
Serum sickness.

1.7 Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis; iris, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis; anterior segment inflammation.

1.8 Respiratory Diseases
Symptomatic sarcoidosis.

1.9 Edematous State
To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.

2 DOSAGE AND ADMINISTRATION

2.1 Specific Recommended Dosage Regimen for Infantile Spasms in Infants and Children Under 2 Years of Age
In the treatment of infantile spasms, Acthar Gel must be administered intramuscularly. The recommended regimen is a daily dose of 150 U/m² (divided into twice daily intramuscular injections of 75 U/m²) administered over a 2-week period. Dosing with Acthar Gel should then be gradually tapered over a 2-week period to avoid adrenal insufficiency. The following is one suggested tapering schedule: 30 U/m² in the morning for 3 days; 15 U/m² in the morning for 3 days; 10 U/m² in the morning for 3 days; 10 U/m² every other morning for 6-days.

Acthar Gel is typically dosed based on body surface area (BSA). For calculation of body surface area, use the following formula

\[ \text{BSA (m}^2) = \frac{\text{weight (kg)} \times \text{height (cm)}}{3600} \]

2.2 Recommended Dosage Regimen for the Treatment of Acute Exacerbations in Adults with Multiple Sclerosis
The recommended dose is daily intramuscular or subcutaneous doses of 80-120 units for 2-3 weeks for acute exacerbations.

Dosage should be individualized according to the medical condition of each patient. Frequency and dose of the drug should be determined by considering the severity of the disease and the initial response of the patient. Although drug dependence does not occur, sudden withdrawal of Acthar Gel after prolonged use may lead to adrenal insufficiency or recurrent symptoms which make it difficult to stop the treatment. It may be necessary to taper the dose and increase the injection interval to gradually discontinue the medication.

2.3 Recommended Dosage Regimen for Other Indications for Adults and Children Over 2 Years of Age
Dosage should be individualized according to the disease under treatment and the general medical condition of each patient. Frequency and dose of the drug should be determined by considering severity of the disease and the initial response of the patient. The usual dose of Acthar Gel is 40-80 units given intramuscularly or subcutaneously every 24-72 hours. Although drug dependence does not occur, sudden withdrawal of Acthar Gel after prolonged use may lead to adrenal insufficiency or recurrent symptoms which make it difficult to stop the treatment. It may be necessary to taper the dose and increase the injection interval to gradually discontinue the medication.

2.4 Preparation
Acthar Gel should be warmed to room temperature before using. Caution should be taken not to over-pressurize the vial prior to withdrawing the product.

3 DOSAGE FORMS AND STRENGTHS
5 mL multi-dose vial containing 80 USP Units per mL.

4 CONTRAINDICATIONS
Acthar Gel is contraindicated for intravenous administration.

Acthar Gel is contraindicated where congenital infections are suspected in infants. Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar Gel. Acthar Gel is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adenocortical insufficiency, adenocortical hyperfunction or sensitivity to proteins of porcine origin.

5 WARNINGS AND PRECAUTIONS
The adverse effects of Acthar Gel are related primarily to its steroidogenic effects. Not all of the adverse events described below have been seen after treatment with Acthar Gel, but might be expected to occur [see Adverse Reactions (6.3)].

5.1 Infections
Adrenal suppression may increase the risks related to infections with any pathogen, including viral, bacterial, fungal, protozoan or helminthic infections. Patients with latent tuberculosis or tuberculin reactivity should be observed closely, and if therapy is prolonged, chemoprophylaxis should be instituted.

5.2 Cushing’s Syndrome and Adrenal Insufficiency Upon Withdrawal
Treatment with Acthar Gel can cause hypothalamic-pituitary-axis (HPA) suppression and Cushing’s syndrome. These conditions should be monitored especially with chronic use.

5.3 Elevated Blood Pressure, Salt and Water Retention and Hypokalemia
Acthar Gel can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium and calcium. Dietary salt restriction and potassium supplementation may be necessary. Caution should be used in the treatment of patients with hypertension, congestive heart failure, or renal insufficiency.

5.4 Vaccination
Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar Gel. Killed or inactivated vaccines may be administered; however, the response to such vaccines can not be predicted. Other immunization procedures should be undertaken with caution in patients who are receiving Acthar Gel, especially when high doses are administered, because of the possible hazards of neurological complications and lack of antibody response.

5.5 Masking Symptoms of Other Diseases
Acthar Gel often acts by masking symptoms of other diseases/disorders without altering the course of the other disease/disorder. Patients should be monitored carefully during and for a period following discontinuation of therapy for signs of infection, abnormal cardiac function, hypertension, hyperglycemia, and hypertension.

5.6 Gastrointestinal Perforation and Bleeding
Acthar Gel can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Signs of gastrointestinal perforation, such as peritoneal irritation, may be masked by the therapy. Use caution where there is the possibility of impeding perforation, abscess or other pyogenic infections, diverticulitis, fresh intestinal anastomoses, and active or latent peptic ulcer.

5.7 Behavioral and Mood Disturbances
Use of Acthar Gel may be associated with central nervous system effects ranging from euphoria, insomnia, irritability (especially in infants), mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated.

5.8 Comorbid Diseases
Patients with a comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar Gel in patients with diabetes and myasthenia gravis.

5.9 Ophthalmic Effects
Prolonged use of Acthar Gel may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves and may enhance the establishment of secondary ocular infections due to fungi and viruses.

5.10 Immunogenicity Potential
Acthar Gel is immunogenic. Limited available data suggest that a patient may develop antibodies to Acthar Gel after chronic administration and loss of endogenous ACTH and Acthar Gel activity. Prolonged administration of Acthar Gel may increase the risk of hypersensitivity reactions. Sensitivity to porcine protein should be considered before starting therapy and during the course of treatment should symptoms arise.

5.11 Use in Patients with Hypothyroidism or Liver Cirrhosis
There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver.
5.12 Negative Effects on Growth and Physical Development
Long-term use of Acthar Gel may have negative effects on growth and physical development in children. Changes in appetite are seen with Acthar Gel therapy, with the effects becoming more frequent as the dose or treatment period increases. These effects are reversible once Acthar Gel therapy is stopped. Growth and physical development of pediatric patients on prolonged therapy should be carefully monitored.

5.13 Decrease in Bone Density
Decrease in bone formation and an increase in bone resorption both through an effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function may occur. These, together with a decrease in the protein matrix of the bone (secondary to an increase in protein catabolism) and reduced sex hormone production, may lead to inhibition of bone growth in children and adolescents and to the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (i.e., postmenopausal women) before initiating therapy, and bone density should be monitored in patients on long term therapy.

5.14 Use in Pregnancy
Acthar Gel has been shown to have an embryocidal effect. Apprise women of potential harm to the fetus [see Use in Specific Populations (8.1)].

6 ADVERSE REACTIONS

Please refer to Adverse Reactions in Infants and Children Under 2 Years of Age (Section 6.1.1) for consideration when treating patients with Infantile Spasms. The adverse reactions presented in Section 6.2 are primarily provided for consideration in use in adults and in children over 2 years of age, but these adverse reactions should also be considered when treating infants and children under 2 years of age.

Acthar Gel causes the release of endogenous cortisol from the adrenal gland. Therefore all the adverse effects known to occur with elevated cortisol may occur with Acthar Gel administration as well. Common adverse reactions include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain.

6.1 Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.

6.1.1 Adverse Reactions in Infants and Children Under 2 Years of Age
While the types of adverse reactions seen in infants and children under age 2 treated for infantile spasms are similar to those seen in older patients, their frequency and severity may be different due to the very young age of the infant, the underlying disorder, the duration of therapy and the dosage regimen. Below is a summary of adverse reactions that occurred at a rate of ≥ 2% in ≥ 1 clinical trial of another drug, and may not reflect the rates observed in practice.

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Recommended 75 U/m² bid n=37 (%)</th>
<th>150 U/m² qd n=37 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular disorders</td>
<td>Hypertension 11 19</td>
<td></td>
</tr>
</tbody>
</table>

* Specific infections that occurred at ≥ 2% were candidiasis, otitis media, pneumonia and upper respiratory tract infections. † In the treatment of Infantile Spasms, other types of seizures/convulsions may occur because some patients with infantile spasms progress to other forms of seizures (for example, Lennox-Gastaut Syndrome). Additionally, the spasms sometimes mask other seizures and once the spasms resolve after treatment, the other seizures may become visible.

These adverse reactions may also be seen in adults and children over 2 years of age when treated for other purposes and with different doses and regimens.

6.2 Postmarketing Experience
The following adverse reactions associated with the use of Acthar Gel have been identified from postmarketing experience with Acthar Gel. Only adverse events that are not listed above as adverse events reported from retrospective chart reviews and non-sponsor conducted clinical trials and those not discussed elsewhere in labeling, are listed in this section. Because the adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to use with Acthar Gel. Events are categorized by system organ class. Unless otherwise noted these adverse events have been reported in infants, children and adults.

6.2.1 Allergic Reactions
Allergic responses have presented as dizziness, nausea and shock (adults only).

6.2.2 Cardiovascular
Necrotizing angiitis (adults only) and congestive heart failure.

6.2.3 Dermatologic
Skin thinning (adults only), facial erythema and increased sweating (adults only).

6.2.4 Endocrine
Decreased carbohydrate tolerance (infants only) and hirsutism.

6.2.5 Gastrointestinal
Pancreatitis (adults only), abdominal distention and ulcerative esophagitis.

6.2.6 General Disorders and Administration Site Conditions
Injection site reactions.

6.2.7 Metabolic
Hypokalemic alkalosis (infants only).

6.2.8 Musculoskeletal
Muscle weakness and vertebral compression fractures (infants only).

6.2.9 Neurological
Headache (adults only), vertigo (adults only), subdural hematoma, intracranial hemorrhage (adults only), and reversible brain shrinkage (usually secondary to hypertension) (infants only).

6.3 Possible Additional Steroidogenic Effects
Based on steroidogenic effects of Acthar Gel certain adverse events may be expected due to the pharmacological effects of corticosteroids. The adverse events that may occur but have not been reported for Acthar Gel are:

6.3.1 Dermatologic
Impaired wound healing, abscess, petechiae and ecchymoses, and suppression of skin test reactions.

6.3.2 Endocrine
Menstrual irregularities.

6.3.3 Metabolic
Negative nitrogen balance due to protein catabolism.

6.3.4 Musculoskeletal
Loss of muscle mass and aseptic necrosis of femoral and humeral heads.

6.3.5 Neurological
Increased intracranial pressure with papilledema, (pseudo-tumor cerebri) usually after treatment, and subdural effusion.

6.3.6 Ophthalmic
Exophtalmos.

7 DRUG INTERACTIONS
Formal drug-drug interaction studies have not been performed. Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Pregnancy Class C: Acthar Gel has been shown to have an embryocidal effect. There are no adequate and well-controlled studies in pregnant women. Acthar Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

8.3 Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Acthar Gel, when treating a nursing mother, a decision should be made whether to discontinue nursing or to discontinue the drug, considering the risk and benefit to the mother.
Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children less than 2 years of age. Both serious and other adverse reactions in this population are discussed in Warnings and Adverse Reactions in Infants and Children Under 2 Years of Age [see Sections 5 and 6.1.1].

The efficacy of Acthar Gel for the treatment of infantile spasms in infants and children less than 2 years of age was evaluated in a randomized, single blinded (video EEG interpreted blinded) clinical trial and an additional active control supportive trial [see Clinical Studies (14)]. A responding patient was defined as having both complete cessation of spasms and elimination of hypsarrhythmia.

Safety in the pediatric population for infantile spasms was evaluated by retrospective chart reviews and data from non-sponsor conducted clinical trials [see Adverse Reactions (6.1.1)]. While the types of adverse reactions seen in infants and children under 2 years of age treated for infantile spasms are similar to those seen in older patients, their frequency and severity may be different due to the very young age of the infant, the underlying disorder, the duration of therapy and the dosage regimen. Effects on growth are of particular concern [see Warnings and Precautions (5.12)]. Serious adverse reactions observed in adults may also occur in children [see Warnings and Precautions (5)].

10 OVERDOSAGE

While chronic exposure to Acthar Gel at high doses can be associated with a variety of potential serious adverse effects, it is not expected that a single high dose, or even several large doses, will cause the potential for serious adverse effects compared to a standard dose. There have been no reports of death or acute overdose symptoms from Acthar Gel in clinical studies or in the published literature.

The intramuscular route of administration makes it unlikely that an inadvertent acute overdose will occur. The typical daily dose of Acthar Gel to treat an infant that has a BSA of 0.4 m² would be 60 U/day. Using the 1-c c syringe supplied with Acthar Gel, the maximum amount that can be injected is 80 U Injection, which is a well-tolerated single dose.

11 DESCRIPTION

Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides. The Acthar Gel manufacturing process converts the initial porcine pituitary extract with ACTH into a mixture having modified porcine ACTH and other related peptide analogs solubilized in gelatin. A major component in the formulated complex mixture is N-25 deamidated porcine ACTH (1-39).

Acthar Gel is supplied as a sterile preparation in 16 mL gelatin to provide a prolonged release after intramuscular or subcutaneous injection. Acthar Gel also contains 0.5% phenol, not more than 0.1% cysteine (added), sodium hydroxide and/or acetic acid to adjust pH and water for injection.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of Acthar Gel in the treatment of infantile spasms is unknown. Acthar Gel and endogenous ACTH stimulate the adrenal cortex to secrete cortisol, corticosterone, dehydroepiandrosterone and a number of weak androgens. Prolonged administration of large doses of Acthar Gel induces hyperplasia and hyper trophy of the adrenal cortex and continuous high output of cortisol, corticosterone and weak androgens. The release of endogenous ACTH is under the influence of the nervous system via the regulatory hormone released from the hypothalamus and by a negative corticosteroid feedback mechanism. Endogenous cortisol suppresses ACTH release.

Acthar Gel is also reported to bind to melanocortin receptors. The trophic effects of endogenous ACTH and Acthar Gel on the adrenal cortex are not well understood beyond the fact that they appear to be mediated by cyclic AMP.

ACTH rapidly disappears from the circulation following its intravenous administration; in people, the plasma half-life is about 15 minutes. The pharmacokinetics of Acthar Gel have not been adequately characterized.

The maximal effects of a trophic hormone on a target organ are achieved when optimal amounts of hormone are acting continuously. Thus, a fixed dose of Acthar Gel will demonstrate a linear increase in adenocortical secretion with increasing duration for the infusion.

13 NONCLINICAL TOXICOLGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Adequate and well-controlled studies have not been done in animals. Human use has not been associated with an increase in malignant disease [see Warnings and Precautions (5.14) and Use in Specific Populations (8.1)].

14 CLINICAL STUDIES

The effectiveness of Acthar Gel as a treatment for infantile spasms was demonstrated in a single blinded (video EEG interpreter blinded) clinical trial in which patients were randomized to receive either a 2 week course of treatment with Acthar Gel (75 U/m² intramuscular twice daily) or prednisone (1 mg/kg by mouth twice daily). The primary outcome was a comparison of the number of patients in each group who were treatment responders, defined as a patient having complete suppression of both clinical spasms and hypsarrhythmia on a full sleep cycle video EEG performed 2 weeks after treatment initiation, rated by an investigator blinded to treatment. Thirteen of 15 patients (86.7%) responded to Acthar Gel as compared to 4 of 14 patients (28.6%) given prednisone (p<0.002). The 2-week treatment was followed by a 2-week period of taper. Nonresponders to the prednisone treatment were eligible to receive Acthar Gel treatment. Seven of 8 patients (87.5%) responded to Acthar Gel after not responding to prednisone. Similarly, the 2 nonresponder patients from the Acthar Gel treatment were eligible to receive treatment with prednisone. One of the 2 patients (50%) responded to the prednisone treatment after not responding to Acthar Gel.

A supportive single-blind, randomized clinical trial comparing high-dose, long-duration treatment (150 U/m² once daily for 3 weeks, n=30) of Acthar Gel with low-dose, short-duration treatment (20 U once daily for 2 weeks, n=29) for the treatment of infantile spasms was also evaluated in infants and children less than 2 years of age. Nonresponders (defined as in the previously described study) in the low-dose group received a dose escalation at 2 weeks to 30 U once daily. Nominal statistical superiority of the high dose treatment, as compared to the low dose treatment, was observed for cessation of spasms but not for the resolution of hypsarrhythmia.

16 HOW SUPPLIED / STORAGE AND HANDLING

Acthar Gel (repository corticotropin injection) is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. Acthar Gel (repository corticotropin injection) should be warmed to room temperature before using. Do not overpressurize the vial prior to withdrawing the product.

Store Acthar Gel (repository corticotropin injection) under refrigeration between 2° to 8°C (36° to 46°F). Product is stable for the period indicated on the label when stored under the conditions described.

17 PATIENT COUNSELING INFORMATION

Caregivers of patients with infantile spasms should be informed of the availability of a Medication Guide, and they should be instructed to read the Medication Guide prior to administering Acthar Gel. Patients should be instructed to take Acthar Gel only as prescribed. They should not stop treatment suddenly unless instructed by their physician to do so.

Patients, their caregivers and families should be advised as to the importance of the need for careful monitoring while on and during titration from Acthar Gel treatment and the importance of not missing scheduled doctor’s appointments.

Patients, their caregivers and families should be advised that if the patient develops an infection or fever they should contact their physician. They should be educated that a fever may not necessarily be present during infection. The patient should also try to limit contact with other people with infections to minimize the risk of infection while taking Acthar Gel [see Warnings and Precautions (5.1) and Adverse Reactions (6.1.1)].

Patients, their caregivers and families should be advised that if the patient experiences an increase in blood pressure they should contact their physician [see Warnings and Precautions (5.3) and Adverse Reactions (6.1.1)].

Patients, their caregivers and families should be advised that the patient may be monitored for signs of adrenal insufficiency such as weakness, fatigue, lethargy, anorexia, weight loss, hypotension, abdominal pain or hyperpigmentation (adults only) after treatment has stopped. Since the recovery of the adrenal gland varies from days to months, patients may need to be protected from the stress of trauma or surgery by the use of corticosteroids during the period of stress [see Warnings and Precautions (5.2)].

Patients should be advised not to be vaccinated with live or killed attenuated vaccines during treatment with Acthar Gel. Additionally, other immunization procedures in patients or in family members who will be in contact with the patient should be undertaken with caution while the patient is taking Acthar Gel [see Warnings and Precautions (5.4)].

Patients, their caregivers and families should be advised that prolonged use of Acthar Gel in children may result in Cushin’s syndrome and associated adverse reactions, may inhibit skeletal growth, and may cause osteoporosis and decreased bone density. If prolonged use is necessary, Acthar Gel should be given intermittently along with careful observation [see Warnings and Precautions (5.2), (5.12), and (5.13) and Adverse Reactions (6.1.1)].

Patients, their caregivers and families should be informed that Acthar Gel may mask symptoms of other diseases/disorders without altering the course of the other disease/disorder. The patient will need to be monitored for the period following discontinuation of therapy for signs of infection, abnormal cardiac function, hypertension, hyperglycemia, change in body weight, and fecal blood loss [see Warnings and Precautions (5.5)].

In the treatment of Infantile Spasms, other types of seizures may occur because some patients with infantile spasms progress to other forms of seizures (for example, Lennox-Gastaut Syndrome). Additionally the spasms sometimes mask other seizures and once the spasms resolve after treatment with Acthar Gel, the other seizures may become visible.

Parents and caregivers should inform their physician of any new onset of seizures so that the seizures resolve after treatment with Acthar Gel, the other seizures may become visible. Parents and caregivers should inform their physician of any new onset of seizures so that the seizures resolve after treatment with Acthar Gel, the other seizures may become visible.